Cardoso F, Costa A, Senkus E et al (2017) 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast 31:244–259. https://doi.org/10.1016/j.breast.2016.10.001

Article  CAS  PubMed  Google Scholar 

Maughan KL, Lutterbie MA, Ham PS (1998) Treatment of breast cancer. N Engl J Med 339:1339–1346. https://doi.org/10.1056/NEJM199810013391407

Article  Google Scholar 

O’Sullivan CC (2015) Overcoming endocrine resistance in hormone-receptor positive advanced breast cancer-the emerging role of CDK4/6 inhibitors. Int J Cancer Clin Res. https://doi.org/10.23937/2378-3419/2/4/1029

Article  PubMed  PubMed Central  Google Scholar 

Rugo HS, Rumble RB, Macrae E et al (2016) Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 34:3069–3103. https://doi.org/10.1200/JCO.2016.67.1487

Article  CAS  PubMed  Google Scholar 

Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and Letrozole in advanced breast cancer. N Engl J Med 375:1925–1936. https://doi.org/10.1056/NEJMOA1607303

Article  CAS  PubMed  Google Scholar 

Cristofanilli M, DeMichele A, Giorgetti C et al (2018) Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. Eur J Cancer 104:21–31. https://doi.org/10.1016/J.EJCA.2018.08.011

Article  CAS  PubMed  Google Scholar 

Sledge GW, Toi M, Neven P et al (2020) The effect of Abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-Negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 6:116–124. https://doi.org/10.1001/JAMAONCOL.2019.4782

Article  PubMed  Google Scholar 

Goetz MP, Toi M, Campone M et al (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35:3638–3646. https://doi.org/10.1200/JCO.2017.75.6155

Article  CAS  PubMed  Google Scholar 

Shimoi T, Nagai SE, Yoshinami T et al (2020) The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer 27:322–331. https://doi.org/10.1007/S12282-020-01085-0

Article  PubMed  Google Scholar 

Pandey K, An HJ, Kim SK et al (2019) Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: a review. Int J Cancer 145:1179–1188. https://doi.org/10.1002/IJC.32020

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herrera-Abreu MT, Palafox M, Asghar U et al (2016) Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res 76:2301–2313. https://doi.org/10.1158/0008-5472.CAN-15-0728

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boulay A, Rudloff J, Ye J et al (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11:5319–5328. https://doi.org/10.1158/1078-0432.CCR-04-2402

Article  CAS  PubMed  Google Scholar 

Gnant M (2012) Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition. Expert Rev Anticancer Ther 12:1579–1589. https://doi.org/10.1586/ERA.12.138

Article  CAS  PubMed  Google Scholar 

Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529. https://doi.org/10.1056/NEJMOA1109653

Article  CAS  PubMed  Google Scholar 

Burris HA, Lebrun F, Rugo HS et al (2013) Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 119:1908–1915. https://doi.org/10.1002/CNCR.28010

Article  CAS  PubMed  Google Scholar 

Cicchiello F, Riva F, Cazzaniga ME et al (2017) Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: new insights beyond clinical trials. The EVA study. Breast 35:115–121. https://doi.org/10.1016/J.BREAST.2017.06.043

Article  Google Scholar 

Moscetti L, Vici P, Gamucci T et al (2016) Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: a multicenter Italian experience. Breast 29:96–101. https://doi.org/10.1016/J.BREAST.2016.07.005

Article  CAS  PubMed  Google Scholar 

Bilici A, Uysal M, Menekse S et al (2022) Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: a Turkish Oncology Group (TOG) Study. Cancer Invest 40:199–209. https://doi.org/10.1080/07357907.2021.2017952

Article  CAS  PubMed  Google Scholar 

Rugo HS, Lerebours F, Ciruelos E et al (2021) Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 22:489–498. https://doi.org/10.1016/S1470-2045(21)00034-6

Article  CAS  PubMed  Google Scholar 

Karacin C, Oksuzoglu B, Demirci A et al (2023) Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy. BMC Cancer. https://doi.org/10.1186/S12885-023-10609-8

Article  PubMed  PubMed Central  Google Scholar 

Kitano S, Honda A, Itoi N, Lee T (2022) Everolimus for treating hormone receptor-positive metastatic breast cancer previously treated with cyclin-dependent kinase 4/6 inhibitors. Anticancer Res 42:3913–3919. https://doi.org/10.21873/ANTICANRES.15885

Article  CAS  PubMed  Google Scholar 

Cook MM, Al Rabadi L, Kaempf AJ et al (2021) Everolimus plus exemestane treatment in patients with metastatic hormone receptor-positive breast cancer previously treated with CDK4/6 inhibitor therapy. Oncologist 26:101–106. https://doi.org/10.1002/ONCO.13609

Article  CAS  PubMed  Google Scholar 

Nichetti F, Marra A, Giorgi CA et al (2020) 337P Efficacy of everolimus plus exemestane in CDK 4/6 inhibitors-pretreated or naïve HR-positive/HER2-negative breast cancer patients: a secondary analysis of the EVERMET study. Ann Oncol 31:S382. https://doi.org/10.1016/j.annonc.2020.08.439

Article  Google Scholar 

Mo H, Renna CE, Moore HCF et al (2022) Real-world outcomes of everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer in patients previously treated with CDK4/6 inhibitors. Clin Breast Cancer 22:143–148. https://doi.org/10.1016/J.CLBC.2021.10.002

Article  CAS  PubMed  Google Scholar 

François-Martin H, Lardy-Cléaud A, Pistilli B et al (2023) Long-term results with everolimus in advanced hormone receptor positive breast cancer in a Multicenter National Real-World Observational Study. Cancers (Basel). https://doi.org/10.3390/CANCERS15041191/S1

Article  PubMed  Google Scholar 

Kahraman S, Erul E, Seyyar M et al (2023) Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer. Future Oncol 19:727–736. https://doi.org/10.2217/FON-2022-1287

Article  CAS  PubMed  Google Scholar 

Dhakal A, Antony Thomas R, Levine EG et al (2020) Outcome of everolimus-based therapy in hormone-receptor-positive metastatic breast cancer patients after progression on Palbociclib. Breast Cancer (Auckl). https://doi.org/10.1177/1178223420944864

Article  PubMed  Google Scholar 

Ji D, Luo Y, Wang J et al (2023) CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis. BMC Cancer. https://doi.org/10.1186/S12885-023-11290-7

Article  PubMed  PubMed Central  Google Scholar